United Therapeutics Co. (NASDAQ:UTHR) Stock Position Raised by Voloridge Investment Management LLC

Voloridge Investment Management LLC lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 47.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,864 shares of the biotechnology company's stock after buying an additional 2,221 shares during the period. Voloridge Investment Management LLC's holdings in United Therapeutics were worth $2,422,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics during the fourth quarter worth about $25,000. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares during the period. State of Wyoming purchased a new position in United Therapeutics during the fourth quarter worth approximately $62,000. Millstone Evans Group LLC purchased a new position in United Therapeutics during the fourth quarter worth approximately $67,000. Finally, Natixis purchased a new position in United Therapeutics during the fourth quarter worth approximately $85,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $316.07, for a total value of $3,476,770.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,625,370.67. The trade was a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,500 shares of company stock valued at $16,923,950. Insiders own 10.30% of the company's stock.

United Therapeutics Trading Down 1.3%

UTHR stock traded down $4.03 during midday trading on Friday, hitting $316.34. 886,326 shares of the company's stock were exchanged, compared to its average volume of 440,593. United Therapeutics Co. has a 12-month low of $266.98 and a 12-month high of $417.82. The firm has a 50 day moving average price of $299.49 and a 200-day moving average price of $334.86. The stock has a market capitalization of $14.27 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $6.17 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. Morgan Stanley raised their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.